<br>        Inclusion Criteria:<br><br>          -  Male or female at least 18 years of age and less than or equal to 70<br><br>          -  Chronic plaque psoriasis for at least 6 months prior to Screening<br><br>          -  Psoriasis Area and Severity Index (PASI) >=12 and body surface area (BSA) >=10% and<br>             Investigator's Global Assessment (IGA) score >=3 on a 5-point scale<br><br>          -  Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy<br><br>          -  Female subjects must be postmenopausal, permanently sterilized or, if of childbearing<br>             potential, must be willing to use a highly effective method of contraception up till<br>             20 weeks after last administration of study drug, and have a negative pregnancy test<br>             at Visit 1 (Screening) and immediately prior to first dose<br><br>          -  Male subjects with a partner of childbearing potential must be willing to use a condom<br>             when sexually active, up till 20 weeks after the last administration of study<br>             medication (anticipated 5 half-lives)<br><br>        Exclusion Criteria:<br><br>          -  Subjects previously participating in a bimekizumab study<br><br>          -  Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced<br>             psoriasis<br><br>          -  History of chronic or recurrent infections, or a serious or life-threatening infection<br>             within the 6 months prior to the Baseline Visit (including herpes zoster)<br><br>          -  High risk of infection in the Investigator's opinion<br><br>          -  Current sign or symptom that may indicate an active infection<br><br>          -  Concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus<br>             (HIV) infection<br><br>          -  Live (includes attenuated) vaccination within the 8 weeks prior to Baseline<br><br>          -  Subjects with concurrent malignancy or history of malignancy during the past 5 years<br>             (except for specific malignant condition as defined in the protocol)<br><br>          -  Primary immunosuppressive conditions<br><br>          -  TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or<br>             current or history of NTMB infection<br><br>          -  Laboratory abnormalities, as defined in the study protocol<br><br>          -  Any condition which, in the Investigator's judgement, would make the subject<br>             unsuitable for inclusion in the study<br><br>          -  Exposure to more than 1 biological response modifier (limited to anti-TNF or<br>             IL-12/-23) or any biologic response modifier during the three months prior to the<br>             Baseline Visit<br><br>          -  Subjects have received previous treatment with any anti-IL-17 therapy for the<br>             treatment of psoriasis or psoriatic arthritis<br><br>          -  Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic<br>             arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic<br>             lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative<br>             colitis are allowed as long as they have no active symptomatic disease at Screening or<br>             Baseline<br><br>          -  Subjects taking psoriatic arthritis medications other than nonsteroidal<br>             anti-inflammatory drugs (NSAIDs) or analgesics<br>